primewell bpc 157 BPC-157 10mg – Research Peptide BPC-157 - NovaPrime Labs
Description
Earlier framings of "0.34 partial agonist at GCGR" or "0.4 softened agonist at GLP-1R" mistook potency ratios (EC50_LY EC50_native) for efficacy multipliers (E_max_LY E_max_native) and are retracted
Application frequency and volume Most protocols call for once or twice daily application
Most current research-context subcutaneous protocols cite 300-500 mcg/day, but no published human pharmacokinetic study has formally evaluated the subcutaneous route
The goal is long-term resilience
Hence, the downstream pathways are targeted for drug development
